Adams: FDA Should Allow Supervised Peptide Compounding
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Americans are using peptide compounds in large and growing numbers, often obtaining them from unregulated online sellers and informal markets without medical supervision, reliable quality controls, or accurate dosing information.
- Kyle Diamantas, the FDA's acting commissioner, faces a Pharmacy Compounding Advisory Committee meeting July 23-24 to consider restoring certain peptides to the list of substances eligible for compounding by licensed 503A pharmacies, with a follow-up meeting scheduled before February 2027.
- The peptide market splits between FDA-approved drugs such as insulin and semaglutide (GLP-1 agonists) and a "dangerous gray zone" of wellness-promoted compounds labeled "research use only" or "not for human consumption" and sold without consistent quality assurance.
- Former U.S. Surgeon General Jerome M. Adams, the 20th to hold the post, argues in the op-ed that prohibition-style approaches push consumers toward riskier, unregulated channels rather than eliminate demand.
- Under the proposed framework, patients would access select peptides only through a licensed clinician who evaluates individual needs, provides balanced information from available studies and animal data, and ensures ongoing outcome monitoring and reporting.
- The framework would require compounded peptides to carry explicit disclaimers and clinicians to document informed patient decisions, generating real-world safety and efficacy data without replacing full FDA approval pathways.
Why it matters: The July 23-24 PCAC vote is the first concrete regulatory decision point on whether the large and growing population of Americans sourcing peptides from gray markets can shift to licensed, clinician-supervised access. Restoring select peptides to 503A compounding eligibility would create quality-controlled supply chains and real-world safety data — patients gain professional oversight, rogue online sellers lose market share.
